MEMORIAL DAY FLASH SALE: 50% OFF BENZINGA PRO
As we honor our freedom, take a stand today. Secure the financial freedom that both you and your family deserve. Get exclusive market moving news for just 50% off. Claim your 50% discount here.
- The FDA has accepted to review Strongbridge Biopharma plc's (NASDAQ: SBBP) marketing application for Recorlev (levoketoconazole) to treat endogenous Cushing's syndrome.
- Earlier than anticipated, the Company received the official Day 74 letter from the FDA. Within the Day 74 letter, the FDA set a Prescription Drug User Fee Act (PDUFA) target action date of January 1, 2022, reflecting a projected 10-month standard review period.
- The letter does not mention a plan to hold an advisory committee meeting.
- Endogenous Cushing's syndrome is a rare endocrine disease caused by chronic elevated cortisol exposure, often resulting from a benign tumor of the pituitary gland.
- Price Action: SBBP shares are up 0.9% at $2.29 during the premarket session on the last check Thursday.
MEMORIAL DAY FLASH SALE: 50% OFF BENZINGA PRO
As we honor our freedom, take a stand today. Secure the financial freedom that both you and your family deserve. Get exclusive market moving news for just 50% off. Claim your 50% discount here.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!